Table 1.
Patient characteristics for respondents who completed at least one post-vaccination symptom survey
| All | No Ca | Ca Dx | On Active Tx | |||||
|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | N | (%) | |
|
| ||||||||
| N Patients | 1753 | 570 | 1183 | |||||
| Gender | ||||||||
| Female | 1072 | (61) | 388 | (68) | 684 | (58) | 116 | (55) |
| Male | 681 | (39) | 182 | (32) | 499 | (42) | 95 | (45) |
| Age, years | ||||||||
| median (IQR) | 67 | (59–74) | 66 | (54–72) | 68 | (61–74) | 66 | (57–73) |
| Race | ||||||||
| African American/Black | 293 | (17) | 56 | (10) | 237 | (20) | 33 | (16) |
| Asian/Indian/Pacific Islander | 61 | (3) | 32 | (6) | 29 | (2) | 6 | (3) |
| Caucasian/White | 1213 | (69) | 369 | (65) | 844 | (71) | 137 | (65) |
| Other Race | 138 | (8) | 70 | (12) | 68 | (6) | 34 | (16) |
| Unknown | 48 | (3) | 43 | (8) | 5 | (0) | 1 | (0) |
| Ethnicity | ||||||||
| Hispanic | 47 | (3) | 21 | (4) | 26 | (2) | 2 | (1) |
| Non-Hispanic | 1625 | (93) | 491 | (86) | 1134 | (96) | 201 | (95) |
| Unknown/missing | 81 | (5) | 58 | (10) | 23 | (2) | 8 | (4) |
| Cancer Type | ||||||||
| Hematologic malignancy | 89 | (8) | 19 | (9) | ||||
| Solid malignancy | 1094 | (92) | 192 | (91) | ||||
| Type of Treatment* | ||||||||
| Surgery | 51 | (24) | ||||||
| Radiation | 38 | (18) | ||||||
| Chemotherapy | 84 | (40) | ||||||
| Immunotherapy | 35 | (17) | ||||||
| Hormone Therapy | 125 | (59) | ||||||
| Targeted Therapy | 51 | (24) | ||||||
*
Patients could receive more than one type of treatment